Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard
South San Francisco
281 articles about Titan Pharmaceuticals, Inc.
- Double-Digit Increase in Probuphine Shipments -
Titan Pharmaceuticals, Inc. announced today that it has filed an amendment to its certificate of incorporation that will effect a 1-for-6 reverse stock split of the company's issued and outstanding shares of common stock, warrants and options, which was approved by the company's stockholders at a special meeting held on January 23, 2019.
Titan Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2018, and provided an update on its business.
Management Team to Host Conference Call Nov. 14 at 4:15 p.m. EST / 1:15 p.m. PST
Former President and COO of Celgene to Help Guide Pipeline and Corporate Development Activities.
Mr. Hallberg will be responsible for leading all of the company's commercial activities.
Titan Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering with expected total gross proceeds of $9,500,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Titan And The Nevada Center For Behavioral Health Collaborate To Evaluate Probuphine® Treament Of OUD Patients Within The State Of Nevada Criminal Justice System
Titan Pharmaceuticals, Inc. today announced the initiation of a pilot program in collaboration with the Nevada Center for Behavioral Health (NCBH) to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today reported financial results for the second quarter ended June 30, 2018, and provided an update on its business.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into an amendment (the "Amendment") of the previously announced definitive asset purchase, supply and support agreement (the "Purchase Agreement") with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®.
An independent Data Safety Monitoring Board (DSMB) recommended that Titan Pharmaceuticals’ Phase I/II trial of its ropinirole implant for Parkinson’s disease continue with a second cohort of patients. However, the company has decided to temporarily halt the study and focus on another asset.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that the independent Data Safety Monitoring Board ("DSMB") for the company's Phase 1/2 trial...
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada.
Titan develops proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology.
Titan Management Team to Host Conference Call April 2 at 4:15 p.m. EDT / 1:15 p.m. PDT
Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories
Titan Pharmaceuticals, Inc. announced that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A.
Pursuant to this amendment, Titan will prepay $3M of the outstanding $7M principle amount, with an additional $1M prepayment due on the earlier of.
Braeburn's receipt of a CRL from the FDA regarding the NDA for its injectable buprenorphine product is likely to negatively impact Braeburn's Probuphine marketing activities as it focuses on addressing the CRL.
The acceptance marks the beginning of the EMA's regulatory review process for Probuphine for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.
Titan reported approximately $40,000 in license revenue from royalties earned on net sales of Probuphine by Braeburn, compared with approximately $26,000 in the same period a year ago.